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Abstract
Background: Venous leg ulcers (VLUs) are the commonest cause of leg ulceration, affecting 1 in 100 adults. There
is a significant health burden associated with VLUs – it is estimated that the cost of treatment for 1 ulcer is up to
£1300 per year in the NHS. The mainstay of treatment is with graduated compression bandaging; however, treatment
is often prolonged and up to one quarter of venous leg ulcers do not heal despite standard care. Two previous trials
have suggested that low-dose aspirin, as an adjunct to standard care, may hasten healing, but these trials were small
and of poor quality. Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of
VLUs remains to be established.
Methods/Design: AVURT is a phase II randomised double blind, parallel-group, placebo-controlled efficacy trial.
The primary objective is to examine whether aspirin, in addition to standard care, is effective in patients with
chronic VLUs (i.e. over 6 weeks in duration or a history of VLU). Secondary objectives include feasibility and
safety of aspirin in this population. A target of 100 participants, identified from community leg ulcer clinics
and hospital clinics, will be randomised to receive either 300 mg of aspirin once daily or placebo. All participants will
receive standard care with compression therapy. The primary outcome will be time to healing of the reference ulcer.
Follow-up will occur for a maximum of 27 weeks. The primary analysis will use a Cox proportional hazards model to
compare time to healing using the principles of intention-to-treat. Secondary outcomes will include ulcer size, pain
evaluation, compliance and adverse events.
Discussion: The AVURT trial will investigate the efficacy and safety of aspirin as a treatment for VLU and will inform
on the feasibility of proceeding to a larger phase III study. This study will address the paucity of information currently
available regarding aspirin therapy to treat VLU.
Trial registration: The study is registered on a public database with clinicaltrials.gov (NCT02333123; registered
on 5 November 2014).
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Background
Venous leg ulcers (VLUs) are wounds of the lower limb
caused by a diseased venous system, typically occurring
in the gaiter area of the leg. VLUs represent the most
common cause of leg ulceration, with a lifetime preva-
lence of 1–3 % in UK adults and accounting for around
85 % of all lower limb ulcers [1].
Many VLUs take over 6 months to heal; one large study
demonstrated a median time to ulcer healing of 99 days
with 2-layer compression therapy [2]. In addition, more
than a quarter fail to heal completely [3] and the 12-
month recurrence rate of healed VLUs may be up to 28 %
[4, 5]. Patients with longstanding, large ulcers, or who
have a prior history of ulceration, are particularly resistant
to healing [6, 7]. VLUs impair quality of life (QoL); they
are open wounds, which can be large, are often painful,
frequently become infected and leak exudate. Compres-
sion bandaging is an effective treatment [8] but requires
the use of sometimes bulky bandages alongside the need
for regular clinic visits. Health-related QoL is decreased in
patients with VLUs, which can incur significant psycho-
logical morbidity [9], and successful treatment has been
shown to significantly improve QoL [10]. VLUs represent
a significant health economic burden, costing up to £1300
to treat 1 VLU episode for a year in the UK [11]. There is,
therefore, an unmet need for a more cost-effective and
clinically effective treatment for VLUs.
Pathophysiology of venous leg ulcers
In a healthy individual, flow of venous blood back to the
heart occurs via the superficial venous system through the
deep venous system, using the calf muscle pump and the
venous valves to facilitate this flow against gravity. Resting
hydrostatic venous pressure in the lower limb is 80 mmHg
in the standing position, with no pressure gradient. When
exercising, pressure in the deep venous system exceeds 80
mmHg, due to contraction of the calf muscles, forcing
blood flow towards the heart. Valves in the superficial and
perforator venous systems close to prevent retrograde
flow. When the leg muscles relax again, pressure in the
deep system falls below 80 mmHg, allowing blood to flow
from the superficial system to the deep system through
patent valves. Any dysfunction along this pathway may
contribute to the development of venous ulceration.
VLUs most commonly result from impaired venous re-
turn due to calf muscle pump failure, usually as a result
of obstruction or valve dysfunction in the superficial,
deep or perforator venous system in the leg (primary
venous disease). VLUs may also occur following a deep
vein thrombosis or trauma (secondary venous disease).
Other important factors include obesity and immobility.
Pathological maladaptation underlying VLUs include
structural changes in vessel walls such as intimal hyperpla-
sia, increased collagen content in areas of hypertrophy, as
well as reduced smooth muscle cells and extracellular
matrix [12]. These changes are likely triggered by inflam-
mation and contribute to loss of venous tone and, ultim-
ately, venous reflux and hypertension. These structural
changes are also accompanied by cellular changes in the
wound and wound bed – increased proteolytic activity,
platelet aggregation and infiltration of leucocytes into the
dermis, causing dermal fibrosis and leading to cutaneous
changes such as lipodermatosclerosis, haemosiderin de-
position and ulceration. Haemodynamic changes resulting
from venous hypertension also affect the microcirculation,
promoting interstitial oedema and capillary leakage. This
combination of inflammatory activities may cause the
VLU to heal slowly, or not at all. Targeting and reversing
these pathophysiological pathways is the focus of adjunct-
ive drug treatment.
Current treatment of venous leg ulcers
Careful and regular clinical assessment should be the
first step in the management of venous ulceration and
should ideally be performed in a specialised venous ulcer
clinic. All patients should have a venous Duplex scan to
assess for treatable venous disease. Ulcer area and char-
acteristics should be monitored over time, as the chan-
ging nature of an ulcer (depth, area, base, ulcer edge)
can indicate progression of disease or healing. Bacterio-
logical swabs and antibiotics should only be used in
cases of proven clinical infection and a biopsy may be
considered in cases of atypical or non-healing ulceration.
Simple dressings, meticulous wound care and judicious
sharp debridement should be undertaken by experienced
practitioners. All patients with VLUs should have ankle
brachial pressure index (ABPI) performed prior to the
instigation of treatment to exclude arterial disease and
should have cardiovascular risk factors addressed in
the presence of an abnormal ABPI, in addition to referral
to a vascular surgeon. Compression therapy should be in-
stigated and undertaken by an appropriately trained pro-
fessional. According to Scottish Intercollegiate Guidelines
Network (SIGN) guidelines, patients with a chronic non-
healing VLU and concomitant superficial venous reflux
should be referred for consideration for surgery to prevent
recurrence [13].
Compression therapy
The standard treatment of VLUs is multi-layered com-
pression bandaging (aiming for a pressure of 40 mmHg at
the ankle [14] with the aim to reduce venous hyperten-
sion, improve calf muscle function and create a wound
environment that encourages healing whilst reducing
tissue maceration and excessive oedema and moisture.
Compression is recommended as first-line treatment for
VLUs in major UK guidelines [13].
Tilbrook et al. Trials  (2015) 16:513 Page 2 of 9
The ‘gold standard’ is four-layer multi-component
compression therapy [15]; however, this is often con-
sidered unsightly and uncomfortable due to the bulky
nature of the bandages, and may restrict movement at
the ankle, making it difficult to wear shoes. In addition,
poor application technique may reduce the effective-
ness of compression and the negative physical and
social impact of compression stockings may lead to
ambivalence about their effectiveness and subsequently
lead to non-compliance [16]. Two-layer compression
stockings are an alternative to four-layer bandaging
and a recent randomised trial has demonstrated a re-
duction in ulcer recurrence with the two-layer ap-
proach [2, 17]. Various single-layer hosiery are also
available; however, these do not meet the 40-mmHg
targeted compression pressure.
Topical therapy
Topical therapies have been used for VLUs (including
silver-containing antibiotics, zinc oxide and other topical
antimicrobials or impregnated dressings) although there
is no reliable evidence to suggest that complex wound
dressings are better than simple non-adherent dressings
[18]. Topical local anaesthetic creams may help bring
symptomatic relief when the ulcers are painful.
Adjunctive drug treatment
Various drug adjuncts to compression have also been
investigated, with a recent Cochrane Review demon-
strating that pentoxyfilline (a vasodilator that decreases
blood viscosity, modifies leucocyte activity and has
some anti-platelet effects) is effective in improving
wound healing when used with, and possibly without,
four-layer compression [19]. However, vasodilators such
as pentoxyfilline are not routinely prescribed in the
National Health Service (NHS) and may produce in-
tolerable adverse events (AEs), including potentially
life-threatening side effects such as haematemesis,
gastrointestinal haemorrhage and thrombocytopenia
[20]. There is insufficient evidence to recommend the
use of other adjunctive drugs, including venoactive
drugs that increase venous tone via mechanisms that
remain largely unclear.
Aspirin
Aspirin is a cyclooxygenase inhibitor that irreversibly
reduces prostaglandin-2 and thromboxane A2, which are
involved in inflammation and platelet aggregation [21].
It is inexpensive, widely used and readily available. The
mechanism by which aspirin may hasten healing of
VLUs is unclear but may be associated with a reduction
of inflammation, or its effect on the microvascular circu-
lation, including platelet activation. In one study investi-
gating the haemostatic effects of aspirin in patients with
VLU, the investigators demonstrated that participants
were found to have increased levels of fibrinogen and short-
ened coagulation rate, when compared to age-matched and
sex-matched controls and that treatment with aspirin
caused prolongation of the coagulation rate, which in-
creased the rate of ulcer healing [22].
There have been 2 small randomised trials to date that
have investigated the use of aspirin (300 mg) in VLUs;
however, the quality of evidence presented was low and
more robust studies are required to confirm their find-
ings. An additional file outlines the previous studies in-
vestigating aspirin in VLUs (see Additional file 1).
The first study was carried out in 1994 and demon-
strated that 38 % more patients healed in the treatment
group (aspirin plus compression) than in the control
group (placebo plus compression) [23]; however, no pa-
tients healed within 4 months in the control group,
which is surprising, given that the median time to heal-
ing with compression alone is around 3 months [15]. Al-
though it provides some limited data about the potential
use of aspirin therapy, the sample size of only 20 pa-
tients is insufficient to draw meaningful conclusions. In
addition, patients were only followed-up for 4 months.
Over a decade later, a Spanish group conducted a
small randomised pilot trial (n = 51 patients) of aspirin
and compression, demonstrating that aspirin reduced
the average time to healing but did not influence the rate
of healing and had no effect on the rate of ulcer recurrence.
In addition, after multivariate analysis was performed, as-
pirin was not demonstrated to be an independent predictor
of healing [24] with only initial ulcer size at study entry
remaining independently associated with rate of healing.
Moreover, no information was presented regarding the
placebo and there is uncertainty around the effect esti-
mates. The quality of evidence that aspirin hastens healing
of VLUs is, therefore, low and needs addressing through
more robust studies.
In addition to the Aspirin for Venous Ulcers: Rando-
mised Trial (AVURT), there are two ongoing rando-
mised trials investigating the use of aspirin in VLU.
ASPiVLU (ASPirin in Venous Leg Ulcer healing,
ACTRN12614000293662) will investigate the use of
300 mg aspirin, in addition to standard 3-layer com-
pression therapy, with the primary endpoint as the time
to complete ulcer healing at or before 12 weeks from
randomisation. Aspirin4VLU (Low Dose Aspirin for
Venous Leg Ulceration, NCT02158806) will investigate
150 mg aspirin, in addition to routine care, on time to
complete healing of the reference ulcer. In addition to
the trials reporting individually, data from AVURT,
ASPiVLU and Aspirin4VLU will be combined in order
to carry out an individual patient data (IPD) meta-
analysis. Any other relevant trials such as the two earl-
ier trials will also be considered for inclusion.
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Other options: surgery and minimally invasive
intervention
Varicose vein surgery for VLUs has not been shown to in-
fluence the time to VLU healing; however, it may decrease
the rate and severity of recurrence [4, 25],. Minimally in-
vasive techniques such as radiofrequency ablation, foam
sclerotherapy and endovascular laser ablation have largely
replaced traditional open surgical techniques in the treat-
ment of varicose veins, where possible. There have been
no large-scale randomised trials investigating the superior-
ity of one technique over another when treating VLUs,
although recent studies suggest some benefit from radio-
frequency ablation to assist VLU healing [26]. However, a
large multi-centre randomised trial is currently underway
(EVRA – Early Venous Reflux Ablation ulcer trial), aiming
to assess the influence of early endovenous treatment of
superficial venous reflux in patients with VLUs, compared
to standard compression therapy (NIHR HTA 11/129/
197; ISRCTN02335796).
Other options: cell-based therapy, skin grafts and acellular
products
Research on novel treatments with cell-based therapy is
currently in progress, with promising results from phase
II and phase III trials investigating the use of allogenic
cells, either applied topically or via injection onto areas
of ulceration [27, 28] as well as growth factors [29].
However, such therapies are expensive, may be associ-
ated with significant side effects and are unlikely to
become widely available in the near future. Acellular
products, such as porcine mucosa, have been trialled to
assist VLU healing, with promising results noted in one
study [30]. A recent Cochrane Review of skin grafting
for VLU (including autografts, allografts, xenografts and
bioengineered artificial skin grafts) demonstrated that
bilayer tissue-engineered skin replacement, used with
compression, was the only skin grafting technique that
may increase the rate of VLU healing [31], but data are
very limited in this area.
The need for AVURT – a randomised, placebo-controlled
efficacy study
Whilst there have been two small trials to date that have
investigated the use of aspirin in the treatment of VLUs,
the quality of the evidence presented is low. Given the
significant health burden represented by VLUs, and the
challenges in treating the disease, there is a need to
identify effective, inexpensive, safe and widely available
treatments that patients may tolerate. The AVURT seeks
to investigate the effect of aspirin on time to healing of
VLUs, to examine safety issues in this cohort of patients
and to inform on the feasibility of proceeding from a
phase II trial to an efficacy and effectiveness (phase III)
trial. If a simple, cheap and well-tolerated medication,
such as aspirin, were to result in a reduction in time to
healing, this would impact on patient management, re-
source use and the potential impact on the population is
substantial, given that aspirin is widely available. Meta-
analyses have demonstrated that low-dose aspirin in-
creases the risk of major bleeding compared to placebo
[32, 33]; however, the absolute increase is modest and
there is no evidence that decreasing the dose will reduce
the risks of side effects [34]. The study will also provide
the opportunity to systematically review the safety pro-
file of aspirin in this population of patients, as well as
assess the generalisability of the medication by studying
the number of patients with VLUs who are currently tak-
ing aspirin or other anti-platelet medications.
Methods/Design
Trial design
The AVURT is designed to inform the feasibility of a larger,
confirmatory study of aspirin therapy for VLU. AVURT is a
phase II randomised, double blind, parallel-group, placebo-
controlled study to provide evidence regarding the efficacy
and safety of aspirin (at a dose of 300 mg once daily), in
addition to standard care in patients with chronic VLUs. A
chronic VLU is defined as any break in the skin that has ei-
ther: a) been present for more than 6 weeks, or b) occurred
in a person with a history of venous leg ulceration. Ulcers
will be considered venous if no other aetiology is clinically
suspected. The ulcer must be venous in appearance (i.e.
moist, shallow and irregular of appearance) and lie wholly
or partially within the gaiter area of the leg. Potential partic-
ipants will be identified from hospital outpatient clinics or
community leg ulcer clinics, where they usually receive
treatment for VLUs. An additional file shows the schematic
of the AVURT trial design (see Additional file 2). All partic-
ipants will continue to receive ‘standard care’ according to
an evidence-based standardised approach to the manage-
ment of VLUs, as per SIGN guidelines [13] with multi-
component compression therapy aiming to deliver 40
mmHg of pressure at the ankle. The type of dressing used
will be at the discretion of the healthcare professional man-
aging the patient and will be documented in the participant
case report form (CRF).
Aspirin will be provided as a 300-mg capsule identical
in weight, colour and size to the matched placebo cap-
sules. Placebo capsules will contain a lactose and mag-
nesium stearate blend. Capsules will be packaged into
child-resistant tamper evident bottles sufficient in size
to hold 190 doses for the participant to complete 24
weeks treatment.
Ethical approval
Full ethical approval has been granted by the National
Research Ethics Service (NRES) East Midlands –
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Nottingham 2 research ethics committee (REC) (refer-
ence 14/EM/1305).
Screening, eligibility and patient pathway
Screening will be conducted by research nurses, who
will also identify potential participants, gain informed
consent and conduct a baseline assessment. Patients
will be recruited from hospital and community-based
ulcer clinics, and through liaison with general practi-
tioners (GPs), community nurses and hospital staff.
Eligibility will be confirmed by a doctor. The participant
will continue with regular (usually weekly or 2-weekly)
visits to the usual place of ulcer care, where the research
or treating nurse will assess the components involved in
the study. An additional file shows a summary of AVURT
assessments (see Additional file 3).
Inclusion criteria
Inclusion criteria are:
 Patients with at least one chronic venous leg ulcer (if
more than one ulcer, the largest ulcer will be chosen
as the reference ulcer for the purposes of the trial)
 Ulcer area > 1 cm2
 ABPI ≥ 0.8 taken within the previous three months, or
 if the ABPI is incompressible, other forms of clinical
assessment must exclude peripheral arterial disease
(peripheral pulse examination, toe pressure, Duplex
ultrasound, clinical judgement)
 Age over 18 years (no upper age limit)
Informed consent
Exclusion criteria
The exclusion criteria are:
 Unable to provide consent
 Unwilling to provide consent
 Foot ulcer (i.e. below the ankle)
 Leg ulcer of non-venous aetiology
 ABPI < 0.8 or, where ABPI is not compressible,
peripheral arterial disease (PAD) cannot be excluded
by other assessments
 Regular concomitant aspirin
 Previous intolerance or contraindication to aspirin
use (according to prescriber’s clinical judgement)
 Prohibited medication: probenecid; oral
anticoagulants including coumarins (warfarin,
acenocoumarol) and phenindione; dabigatran;
rivaroxaban; apixiban; heparin; clopidogrel;
dipyridamole; sulfinpyrazone and iloprost
 Known lactose intolerance
 Pregnant/lactating women
 Male or pre-menopausal female participants of
child-bearing potential1 unwilling to use an effective
method of birth control (either hormonal in the
form of the contraceptive pill or barrier method of
birth control accompanied by the use of a proprietary
spermicidal foam/gel or film; or agreement of true
abstinence (i.e. withdrawal, calendar, ovulation,
symptothermal and post ovulation are not acceptable
methods) from time of consent is signed until 6
weeks after the last dose of Investigational Medicinal
Product (IMP)
 Already participating in another study investigating
leg ulcer therapy
 Previously been recruited into this trial
 Another reason that excludes them from participating
within this trial (decision made according to the
nurses’ or prescribers’ clinical judgment)
There will be no exceptions (waivers) to eligibility cri-
teria. Participants will be considered eligible if they meet
all of the inclusion criteria and none of the exclusion cri-
teria mentioned above. Details of all screened patients,
whether recruited or not, will be entered onto the spon-
sor screening log.
Consent
The process of consent will be carried out in accordance
with the Declaration of Helsinki. All patients will be fully
informed about the nature of the research study and the
chances of being randomised to either the trial drug (as-
pirin) or placebo. Written information will be provided to
patients, who will have the opportunity to discuss the
study with a member of the trial team prior to enrolment
in the study. Patients will be aware that their decision to
participate in the study is voluntary and that they are free
to withdraw consent at any time with no effect on the
standard treatment they receive. Written consent forms
will be obtained from patients willing to participate in the
study and will be retained by the investigator.
Randomisation and blinding
Participants will be randomised on a 1:1 basis to receive
either aspirin (300 mg) or placebo, in addition to standard
care. The Research Pharmacy responsible for dispensing
all trial medication (St George’s Hospital) will receive a
randomisation schedule generated in advance by the IMP
manufacturer, Sharp Clinical Services UK Ltd. (Sharp
Clinical Services, UK) Stratification will be by ulcer size
(≤5 cm2 or > 5 cm2).
Randomisation will be performed by the Research
Pharmacy upon receipt of a valid prescription for a
participant. Researchers, treating staff, clinicians and
participants will be blind to treatment allocation. A
24-hour code-breaking service will be provided by the
Research Pharmacy in case of requirement for
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emergency unblinding and participants will receive a
study-specific 24-hour emergency contact card.
Sample size calculation
This study aims to recruit 100 patients, which is suffi-
cient to demonstrate whether there is evidence for effi-
cacy of aspirin to treat VLUs, in line with previous
similar trials [23, 24] and is also large enough to test the
feasibility of study procedures such as recruitment.
The primary outcome is time to healing of the reference
ulcer. Applying an assumed standard error for the hazard
ratio (HR) of 0.105 following adjustment for log area and
log duration of ulcer (as in VenUS IV) to the smaller sam-
ple size in this study implies that the standard error would
be 0.22. A 95 % confidence interval (CI) for the log hazard
ratio would thus be log(HR) ± 0.435. Hence, if the hazard
ratio for this study were the same as that suggested by
previous studies (around 1.5), the confidence interval
would be (0.97, 2.31) which just includes 1.00. To further
increase the power an IPD meta-analysis is proposed. As
compliance and follow-up will be measured as part of the
study there is no formal inflation for dropout.
An important secondary outcome is wound area. As-
suming a standard deviation of 1.09 following log trans-
formation as in (VenUS I) [15], 2 groups of 50 participants
will render 80 % power to detect a difference of 0.62 on
the natural log scale. This corresponds to a reduction of
46 % in ulcer area at follow-up. In the current study, there
will be multiple measurements of wound area and so
smaller differences should be detectable.
Primary outcome
The primary outcome is time to ulcer healing, which will
be defined as ‘completed epithelial healing in the absence
of scab (eschar) with no dressing required’. This will take
the form of survival time data for analysis. Time to healing
will be measured in days from the date of randomisation
until the first date that healing is recorded. If healing
occurs before the end of the study, the participant will be
followed for a further 2 weeks to confirm healing, in
accordance with the Food and Drug Administration (FDA)
and European Wound Management Association (EWMA)
guidelines [35]. A digital photograph of the area will be
taken at this point to confirm healing. For patients who
have not healed, time from date of randomisation until
they exit the trial, withdraw, are lost to follow-up or die will
be used in the survival analysis – whichever occurs first.
Secondary outcomes
Secondary outcomes are:
 Ulcer size (area) measured in cm2 using image
analysis by SigmaScan, Systat Software Inc, San Jose,
CA, USA and/or wound tracings
 Recurrence of reference ulcer
 Adverse events (AEs)
 Ulcer-related pain using a visual analogue scale
 Treatment compliance (capsule counting and nurse
assessment of compression concordance)
 Resource use: number of wound consultations and
types of dressings used
Statistical analysis
Analyses will be in accordance with the principles of
intention-to-treat. Analysis will be conducted in Stata®
(Stata Corporation, College Station, TX, USA) or similar
statistical software. Statistical significance will be assessed
at the 2-sided 5 % level unless otherwise stated. Ninety-
five percent CIs will be provided as appropriate. Statistical
analyses will be detailed in an analysis plan that will be in-
dependently reviewed and agreed before data are analysed.
Primary outcome analyses
Time to ulcer healing will be presented by trial arm
using a Kaplan-Meier plot and a log-rank survival com-
parison will be made. The median time to healing will
be presented overall and by trial arm with corresponding
95 % CIs. The primary analysis will investigate differ-
ences between trial arms in relation to time to ulcer
healing using a Cox proportional hazards regression
model. Adjustments will be made for log transformed
area and duration of the reference ulcer. The model will
be tested for inclusion of shared centre frailty effects.
Secondary outcome analyses
Ulcer area will be transformed and investigated on the
natural log scale through mixed models to see whether
there are differences by trial arm.
The proportion of patients who are found to have a re-
currence within the study period will be reported by trial
arm. Time from healing to recurrence will be investigated
in a similar fashion to the primary outcome should num-
bers be sufficient to allow.
AEs will be reported overall and by trial arm in terms
of number of patients with at least one event and total
number of events. Serious and non-serious events will
be presented separately and according to whether they
are thought to be related, or unrelated, to treatment.
Differences in total numbers of events by trial arm will
be compared using negative binomial regression adjust-
ing for size and duration of ulcer.
Mean and median pain scores will be presented by
trial arm and differences in pain scores between the allo-
cated groups will be investigated using linear regression
adjusted for baseline pain score.
Compliance will be reported in terms of proportion of
patients completing the course of treatment up to healing
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or planned trial exit and compared between arms using a
Chi-squared test and 95 % CIs.
Resource use will be presented using summary statis-
tics in relation to the number of wound consultations
per week and change to compression therapy or primary
wound dressings.
Treatment period and follow-up
After consent, participants will be screened to ensure
eligibility. Prior to randomisation, baseline demographic
details will be collected and a clinical assessment of the
patient and wound performed. Following randomisation,
participants will continue in the normal care pathway of
weekly or 2-weekly clinical assessments at community
ulcer clinics, hospital outpatient clinics or home visits
and will not be required to attend any further visits for
research purposes. All randomised participants will
receive aspirin or placebo for 24 weeks and will be
followed-up for 25 weeks following randomisation. If the
reference ulcer is confirmed as healed during the follow-
up period, then a photograph will be taken and the
participant will continue to take the IMP or placebo for
2 further weeks. They will then be re-assessed (as per
FDA and EWMA guidelines on wound healing) [35]. If
the ulcer is confirmed as healed at this reassessment
visit, then the date of ulcer healing will be recorded as
the date that the ulcer was first assessed as healed. The
participant will then be advised to stop taking the IMP
or placebo. If a new ulcer occurs on the reference leg be-
fore the end of the study, then participants will be asked
to inform the study team.
If the ulcer is assessed as ‘not healed’, then the partici-
pant will continue in the trial until the minimum period
of follow-up (25 weeks) has elapsed providing confirmed
healing does not occur before the end of the follow-up
period. Both of these time-points (first healing judgement
and confirmation of ulcer healing) will be recorded.
Participants will also be asked to provide a pain
score using a visual analogue scale at baseline and 4–6
weeks after first dose of IMP. Weekly (or 2-weekly, if
that is the participant’s usual interval of care) assess-
ments will include: healing outcomes, treatment con-
cordance with IMP and compression bandaging, AEs
or side effects, change to concomitant medication, re-
source use (number of visits, types of dressings used
and level of compression). Digital photographs, or leg
ulcer tracings, will also be taken by the treating or re-
search nurse.
Safety reporting
Despite some apparent advantages of aspirin therapy in
the treatment of VLUs, the risks associated with aspirin
will carefully reported. Safety reporting during this trial is
paramount and will be conducted in line with Healthy
Technology Assessment (HTA) guidelines. Reportable
safety events will include any of the following experienced
by a participant during the trial: AE, adverse reaction, ser-
ious adverse event (SAE), serious adverse reaction (SAR),
suspected unexpected SAR. All AEs will be recorded in
the clinic notes, on the study CRF and reported to the
sponsor via the sponsor AE log. SAEs and SARs will be
notified to the sponsor immediately when the investigator
becomes aware of the event (within 24 hours). The spon-
sor will inform the Medicines and Healthcare products
Regulatory Agency (MHRA) and ethics committee, where
appropriate. SAEs will be reported to the trial coordinator
in the York Trials Unit via the sponsor and reviewed by
the data monitoring committee.
All patients who develop unacceptable treatment toxicity
which, in the investigator’s opinion, is attributable to the
IMP or an SAE, will be withdrawn from the study treatment
but follow-up will continue (where appropriate) to enable
an intention-to-treat analysis. The side effects associated
with aspirin are well-known to health professionals and no
additional training will be required. These include, but are
not limited to, gastrointestinal haemorrhage and gastrointes-
tinal disturbance (including dyspepsia, ulceration).
In addition, AEs associated with leg ulceration or com-
pression therapy will be recorded. Pregnancy and breast-
feeding are exclusion criteria for the study; however, all
patients of childbearing age will be advised to use barrier
contraception during the duration of the study.
Discussion/Summary
Chronic VLUs are a common medical problem associ-
ated with considerable morbidity. Current treatment
(using graduated compression therapy) may not result
in sustained wound healing; however, there is inadequate
evidence of other effective alternatives, or adjuncts, to
improve outcomes. Low-dose aspirin (in addition to
standard compression therapy) may hasten healing; how-
ever, current evidence supporting its use is insufficient.
This randomised trial will inform on whether low-dose as-
pirin is an effective, feasible and safe therapy for patients
with chronic VLUs, in addition to standard compression
therapy. This could go some way towards addressing the
significant health burden associated with VLUs.
Trial status
At the time of submission, the trial is open to re-
cruitment. Collaborating centres include St George’s,
University of London; University of York; University
of Manchester; Bradford Teaching Hospitals NHS
Foundation Trust; Harrogate and District NHS Foun-
dation Trust; Hull and East Yorkshire Hospitals NHS
Trust; University of Nottingham; Cardiff University;
Newcastle University.
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Endnote
1Subjects are only considered not of child bearing po-
tential if they are surgically sterile (i.e. they have under-
gone a hysterectomy, bilateral tubal ligation, or bilateral
oophorectomy) or they are postmenopausal.
Additional files
Additional file 1: Table S1. Previous randomised trials investigating
aspirin in the treatment of VLU. (DOCX 15 kb)
Additional file 2: Figure S1. Schematic of AVURT trial design.
(PDF 88 kb)
Additional file 3: Figure S2. Summary flow chart of AVURT assessments.
(PDF 173 kb)
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